Research & Literature

[Triglyceride deposit cardiomyovasculopathy].

Hirano K

Nihon rinsho. Japanese journal of clinical medicine 2013; (71(9)):1676-80.

Newly developed selective immunoinactivation assay revealed reduction in adipose triglyceride lipase activity in peripheral leucocytes from patients with idiopathic triglyceride deposit cardiomyovasculopathy.

Takagi A, Ikeda Y, Kobayashi K, et al.

Biochemical and biophysical research communications 2018; (495(1)):646-651 doi:10.1016/j.bbrc.2017.11.070.

Tricaprin Rescues Myocardial Abnormality in a Mouse Model of Triglyceride Deposit Cardiomyovasculopathy.

Suzuki A, Yamaguchi S, Li M, et al.

Journal of oleo science 2018; (67(8)):983-989 doi:10.5650/jos.ess18037.

Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder.

Li M, Hirano KI, Ikeda Y, et al.

Orphanet journal of rare diseases 2019; (14(1)):134 doi:10.1186/s13023-019-1087-4.

Neutral Lipid Storage Disease Associated with the PNPLA2 Gene: Case Report and Literature Review.

Samukawa M, Nakamura N, Hirano M, et al.

European neurology 2020; (83(3)):317-322 doi:10.1159/000508346.

Prevalence and clinical outcomes of triglyceride deposit cardiomyovasculopathy among haemodialysis patients.

Onishi T, Nakano Y, Hirano KI, et al.

Heart (British Cardiac Society) 2021; (107(2)):127-134 doi:10.1136/heartjnl-2020-317672.

Triglyceride Deposit Cardiomyovasculopathy with Massive Myocardial Triglyceride which Was Proven Using Proton-magnetic Resonance Spectroscopy.

Sai E, Shimada K, Aikawa T, et al.

Internal medicine (Tokyo, Japan) 2021; (60(8)):1217-1220 doi:10.2169/internalmedicine.6126-20.

Outside-in signaling by femoral cuff injury induces a distinct vascular lesion in adipose triglyceride lipase knockout mice.

Noguchi H, Yamada S, Hirano KI, et al.

Histology and histopathology 2021; (36(1)):91-100 doi:10.14670/HH-18-285.

ATGL Deficiency-Induced Triglyceride Deposit Cardiomyovasculopathy Requiring Heart Transplant: A 5-Year Follow-Up.

Rajani P, Robertus JL, Wong J, et al.

JACC. Case reports 2020; (2(5)):760-763 doi:10.1016/j.jaccas.2020.03.021.

Clinical significance of 123I-BMIPP washout rate in patients with uncertain chronic heart failure.

Aoshima C, Fujimoto S, Kudo A, et al.

European journal of nuclear medicine and molecular imaging 2022; (49(9)):3129-3139 doi:10.1007/s00259-022-05749-1.

Methods of calculating 123I-β-methyl-P-iodophenyl-pentadecanoic acid washout rates in triglyceride deposit cardiomyovasculopathy.

Chen Z, Nakajima K, Hirano KI, et al.

Annals of nuclear medicine 2022; (36(11)):986-997 doi:10.1007/s12149-022-01787-9.

Additional diagnostic value of electron microscopic examination in endomyocardial biopsy in patients with suspected non-ischemic cardiomyopathy.

Yamamoto M, Sato K, Murakoshi N, et al.

Journal of cardiology 2023; (81(2)):236-243 doi:10.1016/j.jjcc.2022.09.012.

123I-BMIPP Scintigraphy Shows That CNT-01 (Tricaprin) Improves Myocardial Lipolysis in Patients with Idiopathic Triglyceride Deposit Cardiomyovasculopathy: First Randomized Controlled, Exploratory Trial for TGCV.

Miyauchi H, Hirano KI, Nakano Y, et al.

Annals of nuclear cardiology 2022; (8(1)):67-75 doi:10.17996/anc.22-00167.

A novel homozygous missense mutation in PNPLA2 in a patient manifesting primary triglyceride deposit cardiomyovasculopathy.

Hara Y, Ikeda Y, Kimura H, et al.

Molecular genetics and metabolism reports 2023; (34()):100960 doi:10.1016/j.ymgmr.2023.100960.

1H-MRS to evaluate improved triglyceride accumulation in idiopathic triglyceride deposit cardiomyovasculopathy after CNT-01 (tricaprin/trisdecanion) administration.

Aikawa T, Sai E, Kudo A, et al.

Endocrinology, diabetes & metabolism case reports 2023; (2023(2)).

The Diagnostic Criteria 2020 for Triglyceride Deposit Cardiomyovasculopathy.

Kobayashi K, Sakata Y, Miyauchi H, et al.

Annals of nuclear cardiology 2020; (6(1)):99-104 doi:10.17996/anc.20-00131.

Correlation Perspectives for the Diagnosis of Idiopathic Triglyceride Deposit Cardiomyovasculopathy.

Miyauchi H, Iimori T, Hoshi K, et al.

Annals of nuclear cardiology 2020; (6(1)):33-38 doi:10.17996/anc.20-00128.

Practice recommendation for measuring washout rates in 123I-BMIPP fatty acid images.

Nakajima K, Miyauchi H, Hirano KI, et al.

Annals of nuclear medicine 2024; (38(1)):1-8 doi:10.1007/s12149-023-01863-8.

Modified Algorithm Using Total Count for Calculating Myocardial Washout Rate in Single-Photon Emission Computerized Tomography.

Miyauchi H, Ono R, Iimori T, et al.

Annals of nuclear cardiology 2023; (9(1)):19-25 doi:10.17996/anc.22-00172.

Chronic kidney disease is a major risk factor for mortality in triglyceride deposit cardiomyovasculopathy patients.

Nagasawa Y, Okamura S, Nishimura Y, et al.

Clinical and experimental nephrology 2025; (29(6)):866-871 doi:10.1007/s10157-024-02618-z.

Long-term survival and durable recovery of heart failure in patients with triglyceride deposit cardiomyovasculopathy treated with tricaprin.

Hirano KI, Okamura S, Sugimura K, et al.

Nature cardiovascular research 2025; (4(3)):266-274 doi:10.1038/s44161-025-00611-7.

Visual Differentiation Between Triglyceride Deposit Cardiomyovasculopathy and Old Myocardial Infarction Using Count-Washout Rate Polar Map in Iodine-123-β-Methyl-p-Iodophenyl-Pentadecanoic Acid Scintigraphy.

Ono R, Hoshi K, Miyauchi H, Kobayashi Y

Annals of nuclear cardiology 2025; (11(1)):20-25 doi:10.17996/anc.24-00012.

Diagnostic Principle with Washout Rate of 123I-β-methyl-p-iodophenyl pentadecanoic Acid for Triglyceride Deposit Cardiomyovasculopathy.

Hirano KI, Miyauchi H, Nakajima K

Annals of nuclear cardiology 2025; (11(1)):39-41 doi:10.17996/anc.25-00003.

Triglyceride deposit cardiomyovasculopathy: A new class of cardiovascular disease.

Mori T, Hirano KI, Miyauchi H, et al.

Journal of cardiology 2026; (88(4)):255-267 doi:10.1016/j.jjcc.2026.04.003.

Triglyceride deposit cardiomyovasculopathy as a predictor of vascular failure after coronary intervention in patients with hemodialysis: a preliminary analysis.

Fujimoto M, Nakano Y, Hirano KI, et al.

Renal failure 2026; (48(1)):2650580 doi:10.1080/0886022X.2026.2650580.

Durable Vessel Patency Achieved by Drug-Coated Balloon-Only Percutaneous Coronary Intervention in Triglyceride Deposit Cardiomyovasculopathy.

Uchiumi K, Nakano Y, Katsuki S, et al.

JACC. Case reports 2026; 110636 doi:10.1016/j.jaccas.2026.110636.